In Vivo Hybridization Chain Reaction: proof of principle Xenograft mouse study to demonstrate a nanotechnology based conditional cancer therapy, selectively killing mutant cells, while leaving healthy cells untouched.

体内杂交链式反应：原理证明异种移植小鼠研究展示了基于纳米技术的条件性癌症疗法，选择性杀死突变细胞，同时不影响健康细胞。

• 批准号: 158972173
• 负责人: Dr. Tobias Heinen
• 金额: --
• 依托单位: Division of Engineering and Applied Science
• 依托单位国家: 德国
• 项目类别: Research Fellowships
• 财政年份: 2009
• 资助国家: 德国
• 起止时间: 2008-12-31 至 2011-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/158972173?language=en
• 关键词: Vivo; Hybridization; Chain; Reaction; proof

In Vivo Hybridization Chain Reaction: triggered therapeutics for targeted destruction of cancer cellsHybridization Chain Reaction (HCR) is a new method in nucleic acid based nanotechnology. Two thermodynamically metastable small conditional RNAs (scRNAs) form a long double-stranded RNA polymer, only if a diagnostic RNA target is present. This method can be adapted to selectively kill cancer cells in vitro while leaving other cells untouched. The current aim is to develop a conditional therapy for the treatment of cancer, which recognizes and selectively destroys tumors. Therefore, scRNAs are to be tested in xenograft mouse models. State of the art nanoparticle RNA-delivery systems are used to deliver scRNAs to tumors in vivo.

体内杂交链反应：靶向破坏癌细胞的触发疗法杂交链反应(HCR)是一种基于核酸的纳米技术的新方法。只有在存在诊断RNA靶标的情况下，两个热力学上亚稳态的条件小RNA(ScRNAs)才能形成长的双链RNA聚合物。这种方法可以在体外选择性地杀死癌细胞，而不影响其他细胞。目前的目标是开发一种治疗癌症的条件疗法，这种疗法可以识别并选择性地摧毁肿瘤。因此，scRNAs将在异种移植小鼠模型中进行测试。最先进的纳米颗粒RNA递送系统用于将scRNA递送到体内的肿瘤。